Publications

Les effets céllulaires du NADH

NADH-supplementation decreased pinacidil-primed I K(ATP) in ventricular cardiomyocytes by increasing intracellular ATP

Pelzmann B, Hallström S, Schaffer P, Lang P, Nadlinger K, Birkmayer GD, Vrecko C, Reibnegger G and Koidl B.

Brit. J. Pharm. 2003 139, 749-754.

The Reduced Coenzyme Nicotinamide Adenine Dinucleotide (NADH) repairs DNA damage of PC12 cells induced by doxorubicin

Zhang JR, Vrecko K, Nadlinger K, Storga D, Birkmayer GD, Reibnegger G

J. Tumor Marker Oncol. 1998; 13, 5-17.

X-ray induced LO2 cells damage rescued by new antioxidant NADH

Fa-Quan L, Zhang JR.

World J. Gastorenterol. 2003, 9(8): 1781-1785.

The Reduced Coenzyme Nicotinamide Adenine Dinucleotide (NADH) rescues PC 12 cells from Apoptosis

Zhang JR, Vrecko K, Nadlinger K. Storga D. Birkmayer GD, Reibnegger G

J. Tumor Marker Oncol. 1998; 13(3): 11-24.

The Cytoprotection of Nicotinamide Adenine Dinucleotide (NADH) by the Mitochondrial Regulation Mechanism

Meng Xu, Hang JR, Hui SSC

J. Tumor Marker Oncol. 1998; 17: 167 – 174.

The reduced coenzyme Nicotinamide Adenine Dinucleotide (NADH) prevent hepatic cells from Apoptosis

Meng Xu, Jiren Zhang

Int. Journal of Modern Cancer Therapy 2000: 3, 38 – 41.

The antioxidative capacity of stabilized NADH in humans

Reibnegger G, Greilberger J, Juergens G. and Oettl K.

J. Tumor Marker Oncol. 2003; 18, 37-41.

Oral NADH effects blood pressure, lipid peroxidation and lipid profile in spontaneously hypertensive rats

Busheri N, Taylor J, Lieberman S, Mirdamadi-Zonosi N, Birkmayer G, Preuss HG

Geriat. Nephrol. Urol. 1998; 18(2) 95-100.

Influence of reduced Nicotinamide Adenine Dinucleotide (NADH) on the production of Interleukin-6 by peripheral human blood leucocytes

Nadlinger K, Birkmayer J, Gebauer F, Kunze R

Neuroimmunomodulation, 2002; 9: 203-208.

NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaechromocytoma cells

Vrecko K, Storga D, Birkmayer GD, Möller R, Tarfeit E, Horejsi R, Reibnegger G

Biochimica et Biophysica Acta 1997; 1361: 59-65.

Effects of acute and chronic NADH Administration on Peripheral and Central Norepinenphrine and Dopamine Synthesis in the Rat

Gardier AM

Birkmayer Institute for Parkinson Therapy, Internal Lab Report No. 94070401.

NADH: Sensor of blood flow in brain, muscle and other tissues

Ido Y., Chang K., Woosley TA, Willimanson JR

FASEB, 2001; 15: 1419- 1421.

Reduced nicotinamide nucleotides prevent nitration of tyrosine hydroxylase by peroxinitrite

Kuhn DM, Geddes TJ.

Brain Research 2002; 933: 85-89.

NAD+ dependent repair of damaged DNA by human cell extracts

Satoh MS, Pirier GG, Lindahl T.

Biol. Chem. 1993; 268; 8: 5480-5487.

Stabilité et securité du NADH et son disponibilité à l’organisme

Bioavailability of reduced nicotinamide-adenine-dinucleotide (NADH) in the central nervous system of the anaethesized rat measured by laser-induced fluorescence spectroscopy

Rex A, Hentschke MP, Fink H

Pharmacol. Toxicol. 2002; 90: 220-228.

Zur Entwicklung von stabilen Arzneiformen des Coenzyms NADH für die perorale und parenterale Applikation

Mattern C. Ph.D.

Dissertation Humboldt Universität, Berlin, 1996.

Untersuchungen zur Pharmakokinetik von NADH in vivo und in vitro

Kappes K.

Digitale Dissertation, FU Berlin 2005. ISBN 3-886664-054-4.

On the Safety of Reduced Nicotinamide Adenine Nucleotide (NADH)

Birkmayer JGD, Nadlinger K, Hallström S.

Journal Environmental Pathology, Toxicology and Oncology 2004; 23: 179-194.

Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): A 26-week oral tablet administration of stabilized NADH for chronic toxicity study in rats

Birkmayer JGD, Nadlinger K.

Drugs experimental clinical Research 2002; 28: 185-182.

Applications du NADH

La maladie Parkinson

Nicotinamide adenine dinucleotide (NADH) – a new therapeutic approach to Parkinson’s disease:
Comparison of oral and parenteral application

Birkmayer JGD, Vrecko C, Volc D, Birkmayer W

Acta Neurol Scand. 1993; 87: 32-35.

Stimulation of the endogenous L-dopa biosynthesis – a new principle for the therapy of Parkinson’s disease: the clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH)

Birkmayer JGD, Birkmayer W.

Acta Neurol Scan. 1989; 126:183-187.

Stimulation of dopamine biosynthesis in culture PC12 pheochromocytoma cells by the coenzyme nicotinamide adenine dinucleotide (NADH)

Vrecko K, Birkmayer JGD, Krainz J.

J.Neural.Transm. 1993; 5: 147-156.

Dépression

The reduced nicotinamide adenine dinucleotide (NADH)
as biological antidepressive agent.
Experience with 205 patients

Birkmayer JGD, Birkmayer W

New trends in Clinical Neuropharmacology 1991; 5: 75-86.

Antidepressant-like effect of nicotinamide adenine dinucleotide in the forced swim test in rats

Rex A, Schickert R, Fink H

Pharmacology, Biochemistry and Behaviour 2004; 77: 303-307.

Syndrome de fatigue chronique (CFS)

The therapeutic effect of NADH in patients with Chronic Fatigue Syndrome

Forsyth L, Preuss. H, Carneiro ML, Chiazze R, Birkmayer GD, Bellanti J

Ann. Allergy Asthma and Immunol., 199.9; 82: 185-191.

Functional Herbal Medicines & Dietary Supplements

Mertens G

Nicholas Hall & Company, 2000; S.17-23.

Die Wirkung von oralem NADH bei Symptomen des Chronischen Müdigkeitssyndroms

Birkmayer JGD

Journal Orthomolekulare Medizin, 1999; 2: 107-116.

NADH improves symptoms of patients with chronic fatigue syndrome

Birkmayer JGD

The Original Internist; 1999; 6: 6-8.

La maladie Alzheimer

Treatment of Alzheimer’s Disease with stabilized oral Nicotinamide Adenine Dinucleotide: A randomized, double-blind study

Demarin V, Podobnik-Sarkanji S, Storga-Tomic D, Kay G

Drugs exptl. Clin.Res. 2004; 30: 327-337.

Stabilized NADH improves cognitive impairment of Alzheimer patients

Demarin V, Podobnik-Sarkanji S, Storga-Tomic D, Kay G, Martinic-Popovic,M. Puretic B., Birkmayer JGD

J. Tumor Marker Oncology 2003; 18:43-49.

Improvement of Verbal Fluency in Alzheimer’s Disease After NADH Treatment

Demarin V, Storga-Tomic D, Bosnar-Puretic M, Martinic-Popovic I, Birkmayer J

Proceedings 7th Congress European Society for Clinical Neuropharmacology ed: Medimond 2004; 41-45.

Cancer

NADH in Cancer Prevention and Therapy in Phytopharmaceuticals in Cancer Chemoprevention

Birkmayer JGD, Zhang JR, ed. Bagchi D, Preuss H

CRC Press 2005; chapter 33, 541- 554. 

Performance

Einfluss einer NADH Supplementation auf die muskuläre Energiebereitstellung beim Menschen (Influence of NADH supplementation for the muscular energy supply in humans)

Grathwohl D, Klann M, Müller HM, Schlachter H, Berg A.

Deutsche Zeitschrift für Sportmedizin, 11/2000.

Stabilized NADH improves physical and mental performance
in highly conditioned athletes

Birkmayer GD, Nadlinger K.

J. Tum. Marker Oncol. 2003; 18: 51-55.

Extracellular metabolization of NADH by blood cells correlated with intracellular ATP levels

Nadlinger K, Westerthaler W, Storga-Tomic D, Birkmayer JGD

Biophys. Biochim Acta 2002; 1573: 177-182.

Jet Lag et déficit du sommeil

Assesssing the Efficacy of Pharmaceuticals and Nutraceuticals as Countermeasures for Jet Lag

Virre ES, Kay GG

Abstr. Commun. 7th Conference Int. Society Travel Medicine 2001; FC06.03.

Effectiveness of NADH in Alleviating Effects of Sleep Deprivation
in Healthy Middle-Aged Adults

Moline ML.

Study Abstract Cornell University, Sleep Wake Disorder Center December 2001.

Stabilisiertes NADH verbessert die durch Jet Lag reduzierte Hirnleistung (Stabilized NADH as Counter Measure for Jet Lag)

Birkmayer JGD, Kay GG, Virre ES

Wiener Med. Wochenschr. 2002; 17/18: 450-454.

Jet Lag und Schlafentzug – Verminderung der Hirnleistung
Das Coenzym NADH bessert die Symptome

Birkmayer Joerg

Flugmedizin 2002; 9: 41-44.

Stabilized NADH as Counter-Measure Jet Lag and Sleep Deprivation

Kay GG, Virre ES, Moline M

J. Tumor Marker Oncol. 2001; 16 : 124-125.

Stabilisiertes NADH verbessert die Symptome
von Schlafentzug und Jet Lag

Birkmayer JGD

Med. Welt 2001; 7: 61.

NAD+ and NADH in brain functions, brain diseases and brain aging

Ying W.

Frontiers in Bioscience 2007; 12:1863 – 88.

NAD+ and NADH in cellular functions and cell death

Weihai Ying

Frontiers in Bioscience 2006; 11, 3129 – 3148.

Ménopause

NADH – neue Wege in der Behandlung des klimakterischen Syndroms

Friedrich F, Nadlinger K, Birkmayer JGD, Friedrich F

J. Menopause 2006, 10:10-12.

Coenzym-1 (NADH) verbessert die Symptome des klimakterischen Syndroms

JGD Birkmayer

Geburtsh Frauenheilk 2006; 67

Anti-Ageing

Coenzym 1 (NADH): A Proven Anti-Aging Substance

Birkmayer JGD

Abstr.Comm. 1st European Congress on Anti-Aging Medicine Oct. 18-21, 2006 Vienna, Austria

Coenzym-1 (NADH) – Eine wissenschaftlich bewiesene
Anti-Aging-Substanz

Birkmayer JGD

Prevention and anti aging 2006: 340-348.

Kosmetische und Dermatologische Anwendungen

Ointment Preparation containing NADH in Teleangiectasis

Augustin M, Zschocke I

Final Biometric Report, Universitäts Hautklinik, Freiburg, Germany Okt. 2000.

Monographies sur le NADH

NADH – The energizing Coenzyme

Birkmayer George D.

Keats Good Health, Keats Publishing, Inc. 1998.

NADH – Biologische Funktionen und
ernährungsphysiologische Anwendungen

Joerg Birkmayer

ERNO 2000; 1: 71 – 76

NADH – Alles was Sie über NADH (Coenzym-1) wissen sollten

Univ.Prof. Dr.Dr. Joerg Birkmayer

Eine Broschüre zur Information vom Ärzten und Therapeuten, Eigenverlag, 2009

NADH – the biological hydrogen – the secret of our life energy

Birkmayer George

Basic Health Publications Inc. USA, 2009